Skip to content

US · CV · MEDICAL - DEVICES

CapsoVision, Inc. (CV) intrinsic value and stock valuation

$6.11as of 2026-11-21 · Mkt cap 354.74M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CapsoVision, Inc. DCF and intrinsic value

InvestorsCraft values CV with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CV’s statements →

CapsoVision, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Saratoga, CA 95070 capsovision.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$13.6M
20232025
Net income
-$-25.32M
20232025
Free cash flow
-$-22.95M
20232025
Total equity
$13.3M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$13.6M$11.8M$9.75M
Operating income-$-25.52M-$-19.92M-$-11.35M
Net income-$-25.32M-$-19.9M-$-11.3M
EPSd-$-103.12K-$-515.28K-$-292.59K
Operating cash flow-$-22.86M-$-20.09M-$-10.8M
Capital expenditure-$-90K-$-150K-$-750K
Free cash flow-$-22.95M-$-20.24M-$-11.56M
Total assets$18.2M$16.8M$21.5M
Total debt$890K$1.24M$1.51M
Net debt-$-9.22M-$-8.08M-$-13.04M
Total equity$13.3M-$-129.51M-$-109.84M
Cash and short-term investments$10.1M$9.32M$14.6M
Income statement
202520242023
Revenue$13.6M$11.8M$9.75M
Cost of revenue$6.38M$5.38M$4.26M
Gross profit$7.17M$6.38M$5.49M
Research and development expenses$18.3M$15.1M$9.33M
Selling, general and administrative expenses$14.4M$11.2M$7.5M
Other expenses$0.00$0.00$0.00
Operating expenses$32.7M$26.3M$16.8M
Cost and expenses$39.1M$31.7M$21.1M
Interest income$270K$30K$50K
Interest expense$0.00$0.00$0.00
Depreciation and amortization$570K$520K$390K
Ebitda-$-24.95M-$-19.4M-$-10.96M
Operating income-$-25.52M-$-19.92M-$-11.35M
Total other income/expenses, net$230K$30K$50K
Income before tax-$-25.29M-$-19.89M-$-11.29M
Income tax expense$20K$10K$10K
Net income-$-25.32M-$-19.9M-$-11.3M
Weighted average shares outstanding$245.6M$38.6M$38.6M
Weighted average diluted shares outstanding$245.6M$38.6M$38.6M
Balance sheet
202520242023
Cash and short-term investments$10.1M$9.32M$14.6M
Net receivables$2.5M$2M$1.87M
Inventory$2.99M$2.63M$2.19M
Total current assets$16.7M$14.9M$19.2M
Property, plant and equipment, net$1.45M$1.92M$2.28M
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00
Total non-current assets$1.5M$1.96M$2.33M
Total assets$18.2M$16.8M$21.5M
Accounts payable$1.14M$750K$360K
Short-term debt$410K$350K$280K
Deferred revenue$180K$130K$100K
Total current liabilities$4.43M$1.8M$1.51M
Long-term debt$480K$890K$1.24M
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$480K$144.5M$129.9M
Capital lease obligations$890K$1.24M$1.51M
Total liabilities$4.9M$146.3M$131.4M
Common stock$50K$0.00$0.00
Retained earnings-$-155.66M-$-130.35M-$-110.45M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity$13.3M-$-129.51M-$-109.84M
Total investments$0.00$0.00$0.00
Total debt$890K$1.24M$1.51M
Net debt-$-9.22M-$-8.08M-$-13.04M
Cash flow statement
202520242023
Net income-$-25.32M-$-19.9M-$-11.3M
Depreciation and amortization$570K$520K$390K
Stock-based compensation$830K$160K$40K
Change in working capital$1.19M-$-980K$160K
Accounts receivable-$-480K-$-180K$10K
Inventory-$-360K-$-430K-$-670K
Accounts payable$380K$390K$200K
Net cash provided by operating activities-$-22.86M-$-20.09M-$-10.8M
Investments in property, plant and equipment-$-90K-$-150K-$-750K
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities-$-90K-$-150K-$-750K
Common stock issued$26.8M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$23.6M$15.1M$20.5M
Net change in cash$790K-$-5.24M$9.01M
Cash at end of period$10.1M$9.32M$14.6M
Operating cash flow-$-22.86M-$-20.09M-$-10.8M
Capital expenditure-$-90K-$-150K-$-750K
Free cash flow-$-22.95M-$-20.24M-$-11.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CapsoVision, Inc.

        CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

        CEO
        Kang-Huai Wang
        Employees
        99
        Beta
        -2.37

        Explore

        Frequently asked questions

        What is the intrinsic value of CapsoVision, Inc. (CV)?

        CapsoVision, Inc. (CV) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CV undervalued?

        CV trades at a price of $6.11 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.